Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DARVY LEE MANN

Allopathic & Osteopathic Physicians Pediatrics

NPI
1275832479
CMS profile
1169194
Location
LONGVIEW, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$385.36

18 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $385.36 18

By paying entity

PY2025 · entire year · sorted by reported total

Page 1 of 1; records 1–18 of 18 matching records. This page contains 18 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DARVY LEE MANN

NPI 1275832479 · CMS profile ID 1169194

Allopathic & Osteopathic Physicians / Pediatrics

LONGVIEW, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–18 of 18 matching records. This page contains 18 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1275832479?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DARVY LEE MANN, NPI 1275832479, CMS profile ID 1169194. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–18 of 18 matching records. This page contains 18 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1275832479?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). DARVY LEE MANN, NPI 1275832479, CMS profile ID 1169194. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–18 of 18 matching records. This page contains 18 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1275832479?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
DARVY LEE MANN, NPI 1275832479, CMS profile ID 1169194, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–18 of 18 matching records. This page contains 18 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1275832479?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

18 matching records · $385.36 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 18 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–18 of 18.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Regeneron Healthcare Solutions, Inc. $27.2712/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212982255 CMS
GlaxoSmithKline, LLC. $16.4711/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190732098 CMS
PFIZER INC. $18.0711/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229574965 CMS
Corium, LLC $21.9910/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1185821786 CMS
Collegium Pharmaceutical, Inc. $13.9810/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224145736 CMS
GENZYME CORPORATION $19.0610/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233518272 CMS
Corium, LLC $23.6209/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1185827691 CMS
Corium, LLC $21.1306/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1185818378 CMS
Merck Sharp & Dohme LLC $14.9505/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238139205 CMS
Corium, LLC $28.0604/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1185840848 CMS
Seqirus USA Inc $23.5004/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201083601 CMS
PFIZER INC. $23.7804/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231477025 CMS
Corium, LLC $24.6803/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1185831476 CMS
Merck Sharp & Dohme LLC $16.2303/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238097402 CMS
Corium, LLC $25.2103/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1185833166 CMS
Corium, LLC $27.6802/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1185839968 CMS
PFIZER INC. $21.6202/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229673609 CMS
Seqirus USA Inc $18.0601/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201083593 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $150.59 23
PY2020 $67.15 9
PY2021 $149.63 9
PY2022 $300.49 20
PY2023 $408.04 19
PY2024 $226.96 14
PY2025 $385.36 18

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $59,716.71 24
PY2024 Principal investigator $61,020.88 14
PY2023 Principal investigator $72,104.63 22
PY2022 Principal investigator $325,094.46 64
PY2021 Principal investigator $289,713.17 73
PY2020 Principal investigator $296,305.70 95
PY2019 Principal investigator $139,835.21 55

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

55 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $1,673.29 12/31/2019 Non-covered Recipient Entity
Associated Clinicians Of East Texas
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Late Preterm and Term Infants (MELODY) No dispute reported 06/30/2026 684974577
Principal investigator 1 AstraZeneca Pharmaceuticals LP $170.11 12/31/2019 Non-covered Recipient Entity
Associated Clinicians Of East Texas
MEDI8897 RSV mAb-D5290C00003 Phase 2 / 2b Clinical Trial No dispute reported 06/30/2026 684974581
Principal investigator 1 Merck Sharp & Dohme Corporation $13,675.80 12/19/2019 Non-covered Recipient Entity
DCOL CENTER FOR CLINICAL RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691486741
Principal investigator 1 Merck Sharp & Dohme Corporation $15.34 12/09/2019 Non-covered Recipient Entity
DCOL CENTER FOR CLINICAL RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691533067
Principal investigator 1 Merck Sharp & Dohme Corporation $579.51 12/09/2019 Non-covered Recipient Entity
DCOL CENTER FOR CLINICAL RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691533433
Principal investigator 1 Merck Sharp & Dohme Corporation $758.17 12/09/2019 Non-covered Recipient Entity
DCOL CENTER FOR CLINICAL RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691533435
Principal investigator 1 Merck Sharp & Dohme Corporation $113.05 12/09/2019 Non-covered Recipient Entity
DCOL CENTER FOR CLINICAL RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691533873
Principal investigator 1 PFIZER INC. $3,123.90 12/05/2019 Non-covered Recipient Entity
Associated Clinicians of East Texas PLLC DBA DCOL Center for Clinical Research
A PHASE 2 PLACEBOCONTROLLED RANDOMIZED PROOF OF CONCEPT STUDY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN PREGNANT WOMEN No dispute reported 06/30/2026 671689119
Principal investigator 1 Merck Sharp & Dohme Corporation $11,696.40 11/27/2019 Non-covered Recipient Entity
DCOL CENTER FOR CLINICAL RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691449221
Principal investigator 1 Merck Sharp & Dohme Corporation $390.00 11/26/2019 Non-covered Recipient Entity
DCOL CENTER FOR CLINICAL RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691449225
Principal investigator 1 PFIZER INC. $3,500.90 11/26/2019 Non-covered Recipient Entity
Associated Clinicians of East Texas PLLC DBA DCOL Center for Clinical Research
A PHASE 2 PLACEBOCONTROLLED RANDOMIZED PROOF OF CONCEPT STUDY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN PREGNANT WOMEN No dispute reported 06/30/2026 671689113
Principal investigator 1 PFIZER INC. $438.10 11/22/2019 Non-covered Recipient Entity
Associated Clinicians of East Texas PLLC DBA DCOL Center for Clinical Research
A PHASE 2 PLACEBOCONTROLLED RANDOMIZED PROOF OF CONCEPT STUDY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN PREGNANT WOMEN No dispute reported 06/30/2026 671689115
Principal investigator 1 Merck Sharp & Dohme Corporation $61.00 11/19/2019 Non-covered Recipient Entity
DCOL CENTER FOR CLINICAL RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691472283
Principal investigator 1 Merck Sharp & Dohme Corporation $61.00 11/19/2019 Non-covered Recipient Entity
DCOL CENTER FOR CLINICAL RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691494339
Principal investigator 1 Merck Sharp & Dohme Corporation $1,299.72 11/16/2019 Non-covered Recipient Entity
DCOL CENTER FOR CLINICAL RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691533063
Principal investigator 1 Merck Sharp & Dohme Corporation $92.04 11/16/2019 Non-covered Recipient Entity
DCOL CENTER FOR CLINICAL RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691533405
Principal investigator 1 Merck Sharp & Dohme Corporation $193.80 11/16/2019 Non-covered Recipient Entity
DCOL CENTER FOR CLINICAL RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691533429
Principal investigator 1 Merck Sharp & Dohme Corporation $1,159.02 11/16/2019 Non-covered Recipient Entity
DCOL CENTER FOR CLINICAL RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691533875
Principal investigator 1 Merck Sharp & Dohme Corporation $115.10 11/08/2019 Non-covered Recipient Entity
DCOL CENTER FOR CLINICAL RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691472279
Principal investigator 1 Merck Sharp & Dohme Corporation $115.10 11/08/2019 Non-covered Recipient Entity
DCOL CENTER FOR CLINICAL RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691494333
Principal investigator 1 PFIZER INC. $1,340.30 11/02/2019 Non-covered Recipient Entity
Associated Clinicians of East Texas PLLC DBA DCOL Center for Clinical Research
A PHASE 2 PLACEBOCONTROLLED RANDOMIZED PROOF OF CONCEPT STUDY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN PREGNANT WOMEN No dispute reported 06/30/2026 671689117
Principal investigator 1 Merck Sharp & Dohme Corporation $3,958.80 10/29/2019 Non-covered Recipient Entity
DCOL CENTER FOR CLINICAL RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691406599
Principal investigator 1 PFIZER INC. $9,578.40 10/23/2019 Non-covered Recipient Entity
Associated Clinicians of East Texas PLLC DBA DCOL Center for Clinical Research
A PHASE 2 PLACEBOCONTROLLED RANDOMIZED PROOF OF CONCEPT STUDY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN PREGNANT WOMEN No dispute reported 06/30/2026 671689163
Principal investigator 1 Merck Sharp & Dohme Corporation $5,417.60 10/17/2019 Non-covered Recipient Entity
DCOL CENTER FOR CLINICAL RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691405593
Principal investigator 1 Merck Sharp & Dohme Corporation $3,297.00 10/17/2019 Non-covered Recipient Entity
DCOL CENTER FOR CLINICAL RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691406591
Principal investigator 1 Merck Sharp & Dohme Corporation $3,440.00 10/17/2019 Non-covered Recipient Entity
DCOL CENTER FOR CLINICAL RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691406597
Principal investigator 1 AstraZeneca Pharmaceuticals LP $34,632.40 10/15/2019 Non-covered Recipient Entity
Associated Clinicians Of East Texas
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Late Preterm and Term Infants (MELODY) No dispute reported 06/30/2026 684974567
Principal investigator 1 Merck Sharp & Dohme Corporation $772.68 10/05/2019 Non-covered Recipient Entity
DCOL CENTER FOR CLINICAL RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691518811
Principal investigator 1 Merck Sharp & Dohme Corporation $129.20 10/05/2019 Non-covered Recipient Entity
DCOL CENTER FOR CLINICAL RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691533061
Principal investigator 1 Merck Sharp & Dohme Corporation $866.48 10/05/2019 Non-covered Recipient Entity
DCOL CENTER FOR CLINICAL RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691533397
Principal investigator 1 Merck Sharp & Dohme Corporation $92.04 10/05/2019 Non-covered Recipient Entity
DCOL CENTER FOR CLINICAL RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691533401
Principal investigator 1 PFIZER INC. $7,996.30 10/02/2019 Non-covered Recipient Entity
Associated Clinicians of East Texas PLLC DBA DCOL Center for Clinical Research
A PHASE 2 PLACEBOCONTROLLED RANDOMIZED PROOF OF CONCEPT STUDY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN PREGNANT WOMEN No dispute reported 06/30/2026 671689167
Principal investigator 1 Merck Sharp & Dohme Corporation $758.17 09/04/2019 Non-covered Recipient Entity
DCOL CENTER FOR CLINICAL RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691405585
Principal investigator 1 Merck Sharp & Dohme Corporation $107.38 09/04/2019 Non-covered Recipient Entity
DCOL CENTER FOR CLINICAL RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691406681
Principal investigator 1 Merck Sharp & Dohme Corporation $113.05 09/04/2019 Non-covered Recipient Entity
DCOL CENTER FOR CLINICAL RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691455397
Principal investigator 1 Merck Sharp & Dohme Corporation $17.40 08/28/2019 Non-covered Recipient Entity
DCOL CENTER FOR CLINICAL RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691355867
Principal investigator 1 Merck Sharp & Dohme Corporation $579.51 08/22/2019 Non-covered Recipient Entity
DCOL CENTER FOR CLINICAL RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691406565
Principal investigator 1 Merck Sharp & Dohme Corporation $46.02 08/22/2019 Non-covered Recipient Entity
DCOL CENTER FOR CLINICAL RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691406605
Principal investigator 1 Merck Sharp & Dohme Corporation $48.45 08/22/2019 Non-covered Recipient Entity
DCOL CENTER FOR CLINICAL RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691406659
Principal investigator 1 Merck Sharp & Dohme Corporation $324.93 08/22/2019 Non-covered Recipient Entity
DCOL CENTER FOR CLINICAL RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691406685
Principal investigator 1 Merck Sharp & Dohme Corporation $541.55 07/20/2019 Non-covered Recipient Entity
DCOL CENTER FOR CLINICAL RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691406561
Principal investigator 1 Merck Sharp & Dohme Corporation $148.80 07/19/2019 Non-covered Recipient Entity
DCOL CENTER FOR CLINICAL RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691504501
Principal investigator 1 PFIZER INC. $9,500.00 07/19/2019 Non-covered Recipient Entity
Associated Clinicians of East Texas PLLC DBA DCOL Center for Clinical Research
A PHASE 2 PLACEBOCONTROLLED RANDOMIZED PROOF OF CONCEPT STUDY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN PREGNANT WOMEN No dispute reported 06/30/2026 671689165
Principal investigator 1 Merck Sharp & Dohme Corporation $541.55 07/12/2019 Non-covered Recipient Entity
DCOL CENTER FOR CLINICAL RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691406663
Principal investigator 1 Merck Sharp & Dohme Corporation $76.70 06/07/2019 Non-covered Recipient Entity
DCOL CENTER FOR CLINICAL RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691405589
Principal investigator 1 Merck Sharp & Dohme Corporation $80.75 06/07/2019 Non-covered Recipient Entity
DCOL CENTER FOR CLINICAL RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691405597
Principal investigator 1 Merck Sharp & Dohme Corporation $965.85 06/07/2019 Non-covered Recipient Entity
DCOL CENTER FOR CLINICAL RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691452203
Principal investigator 1 Merck Sharp & Dohme Corporation $541.55 06/07/2019 Non-covered Recipient Entity
DCOL CENTER FOR CLINICAL RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691455403
Principal investigator 1 Merck Sharp & Dohme Corporation $167.40 06/06/2019 Non-covered Recipient Entity
DCOL CENTER FOR CLINICAL RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691481119
Principal investigator 1 Merck Sharp & Dohme Corporation $149.70 05/29/2019 Non-covered Recipient Entity
DCOL CENTER FOR CLINICAL RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691348365
Principal investigator 1 Merck Sharp & Dohme Corporation $386.10 05/23/2019 Non-covered Recipient Entity
DCOL CENTER FOR CLINICAL RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691348373
Principal investigator 1 Merck Sharp & Dohme Corporation $1,500.00 05/16/2019 Non-covered Recipient Entity
DCOL CENTER FOR CLINICAL RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691348369
Principal investigator 1 Merck Sharp & Dohme Corporation $4,500.00 05/16/2019 Non-covered Recipient Entity
DCOL CENTER FOR CLINICAL RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691348377
Principal investigator 1 Merck Sharp & Dohme Corporation $500.00 05/16/2019 Non-covered Recipient Entity
DCOL CENTER FOR CLINICAL RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 691348443
Principal investigator 1 AstraZeneca Pharmaceuticals LP $7,487.80 01/23/2019 Non-covered Recipient Entity
Associated Clinicians Of East Texas
MEDI8897 RSV mAb-D5290C00003 Phase 2 / 2b Clinical Trial No dispute reported 06/30/2026 684974573